Avacta Group

Update in progress

AVCT.L (LSE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Avacta Group plc and its subsidiaries develop cancer therapies and diagnostics in the UK, South Korea, and globally. Its lead candidate, AVA6000, is a peptide-drug conjugate form of doxorubicin, an approved cancer drug with known toxicities. The company is also developing AVA6103 to deliver exatecan, a topoisomerase I inhibitor, directly to tumors, and AVA7100 to target fibroblast activation protein–expressing tumors. Incorporated in 2003, based in London.

Company score

Sentiment: 0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive